RHT Stock Overview
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Resonance Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.081 |
| 52 Week High | AU$0.09 |
| 52 Week Low | AU$0.037 |
| Beta | 1.37 |
| 1 Month Change | 15.71% |
| 3 Month Change | 44.64% |
| 1 Year Change | 92.86% |
| 3 Year Change | -56.22% |
| 5 Year Change | -37.69% |
| Change since IPO | 68.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHT | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 2.5% | 1.5% | -0.06% |
| 1Y | 92.9% | 14.7% | 4.3% |
Return vs Industry: RHT exceeded the Australian Medical Equipment industry which returned 14.7% over the past year.
Return vs Market: RHT exceeded the Australian Market which returned 4.3% over the past year.
Price Volatility
| RHT volatility | |
|---|---|
| RHT Average Weekly Movement | 12.5% |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: RHT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RHT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Andrew Harrison | www.resonancehealth.com |
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also provides quantitative imaging measurements and CRO services, such as quality-assured image analysis, project and data management, and issue resolution services; biomarkers, genomics, and laboratory analysis services, as well as works with third party pathology laboratories for blood/sample collection and for standard biochemical/lab safety assessments; design and protocol development, and project management and monitoring services; assessment of subject inclusion or exclusion, evaluating the safety profile of a new therapy, and supporting primary and secondary end-points demonstrating drug efficacy services; and phantoms for the MRI machines.
Resonance Health Limited Fundamentals Summary
| RHT fundamental statistics | |
|---|---|
| Market cap | AU$36.20m |
| Earnings (TTM) | -AU$1.09m |
| Revenue (TTM) | AU$5.64m |
6.4x
P/S Ratio-33.3x
P/E RatioIs RHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHT income statement (TTM) | |
|---|---|
| Revenue | AU$5.64m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$5.64m |
| Other Expenses | AU$6.72m |
| Earnings | -AU$1.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0024 |
| Gross Margin | 100.00% |
| Net Profit Margin | -19.27% |
| Debt/Equity Ratio | 0% |
How did RHT perform over the long term?
See historical performance and comparison